{
  "id": "54fc9ca16ad7dcbc12000006",
  "type": "list",
  "question": "Which receptors are targeted by suvorexant?",
  "ideal_answer": "Suvorexant is a potent, selective, and orally bioavailable antagonist of orexin 1 receptor and orexin 2 receptor currently under clinical investigation as a novel therapy for insomnia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24215799",
    "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
    "http://www.ncbi.nlm.nih.gov/pubmed/24680372",
    "http://www.ncbi.nlm.nih.gov/pubmed/23024835",
    "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
    "http://www.ncbi.nlm.nih.gov/pubmed/22920041",
    "http://www.ncbi.nlm.nih.gov/pubmed/25489915",
    "http://www.ncbi.nlm.nih.gov/pubmed/25147058",
    "http://www.ncbi.nlm.nih.gov/pubmed/22725839",
    "http://www.ncbi.nlm.nih.gov/pubmed/23197752",
    "http://www.ncbi.nlm.nih.gov/pubmed/23692283",
    "http://www.ncbi.nlm.nih.gov/pubmed/25407283",
    "http://www.ncbi.nlm.nih.gov/pubmed/23359095",
    "http://www.ncbi.nlm.nih.gov/pubmed/25197807",
    "http://www.ncbi.nlm.nih.gov/pubmed/25533960",
    "http://www.ncbi.nlm.nih.gov/pubmed/24757363",
    "http://www.ncbi.nlm.nih.gov/pubmed/25397996",
    "http://www.ncbi.nlm.nih.gov/pubmed/24942635",
    "http://www.ncbi.nlm.nih.gov/pubmed/21528938",
    "http://www.ncbi.nlm.nih.gov/pubmed/25227290",
    "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
    "http://www.ncbi.nlm.nih.gov/pubmed/25291725",
    "http://www.ncbi.nlm.nih.gov/pubmed/21473737",
    "http://www.ncbi.nlm.nih.gov/pubmed/23731216",
    "http://www.ncbi.nlm.nih.gov/pubmed/23372274",
    "http://www.ncbi.nlm.nih.gov/pubmed/24550770"
  ],
  "snippets": [
    {
      "text": "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical trials in volunteers and primary insomnia patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several such compounds have entered into clinical development, including the dual orexin receptor antagonists, suvorexant and almorexant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Suvorexant (MK-4305) is an orexin receptor antagonist being developed for the treatment of insomnia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Indeed, phase III clinical trials were completed last year of suvorexant, a non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and demonstrate promising results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We evaluated suvorexant, an orexin receptor antagonist, for treating patients with primary insomnia in a randomized, double-blind, placebo-controlled, 2-period (4 weeks per period) crossover polysomnography study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23197752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024835",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Merck's suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920041",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22725839",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21528938",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21528938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473737",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant is a pharmacologically novel dual antagonist of orexin receptors OX1R and OX2R, which has an effect that promotes sleep by reducing arousal and wakefulness.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25291725",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Indeed, phase III clinical trials were completed last year of suvorexant, a non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and demonstrate promising results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In order to understand the differential contribution of both receptors in regulating sleep/wakefulness states we compared the pharmacological effects of a newly developed OX2R antagonist (2-SORA), Compound 1 m (C1 m), with those of a dual orexin receptor antagonist (DORA), suvorexant, in C57BL/6J mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24550770",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473737",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "orexin 1, orexin 2"
}